ASLAN Pharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASLN research report →
About the company
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions.
- CEO
- Carl Alan Jason Morton Firth EMBA,
- IPO
- 2018
- Employees
- 35
- HQ
- Singapore, SG
Price Chart
- Market Cap
- $777.12M
- P/E
- -0.06
- P/S
- 64.76
- P/B
- -0.19
- EV/EBITDA
- -19.86
- Div Yield
- 0.00%
- Gross Margin
- 97.10%
- Op Margin
- -364.46%
- Net Margin
- -368.50%
- ROE
- 1796.92%
- ROIC
- -323.05%
- Revenue
- $12.00M · 0.00%
- Net Income
- $-44,219,604 · 13.94%
- EPS
- $-10.76 · 26.90%
- Op Income
- $-43,735,600
- FCF YoY
- -20.66%
- 52W High
- $17.04
- 52W Low
- $0.47
- 50D MA
- $1.07
- 200D MA
- $3.48
- Beta
- 1.40
- Avg Volume
- 102.49K
Get TickerSpark's AI analysis on ASLN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ASLN coverage
Recent articles, reports, and earnings notes.
No research on ASLN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ASLN report →Similar companies
Peers in the same neighborhood.